[Ketamine and other N-methyl-D-aspartate receptor modulators in treatment of depression].
Ketamin und andere N-Methyl-D-Aspartat-Rezeptor-Modulatoren zur Behandlung der Depression.
Affective disorders
Glutaminergic system
Rapid-acting antidepressants
Target structures
Treatment resistance
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
05
10
2021
pubmed:
5
11
2021
medline:
9
3
2022
entrez:
4
11
2021
Statut:
ppublish
Résumé
Since the first successful ketamine application in treatment-resistant depressive patients, the newly developed pharmaceutical class of rapid-acting antidepressants has been intensively investigated. The underlying mechanism of action by influencing the glutamatergic neurotransmission via a modulation of N‑methyl-D-aspartate (NMDA) receptors, represents a completely new and promising interventional strategy in the treatment of affective disorders. In this very dynamic field, Spravato® (esketamine) is so far the only approved drug; however, many other substances are currently in the development and evaluation processes. This narrative review provides a critical overview of the most important substances, target structures and developmental stages of NMDAR modulators. Seit den ersten erfolgreichen Ketaminbehandlungen therapieresistenter depressiver Patienten werden schnell wirksame Antidepressiva intensiv beforscht. Der zugrunde liegende Wirkmechanismus der Beeinflussung des glutamatergen Systems, vorwiegend durch eine Modulation von N‑Methyl-D-Aspartat-Rezeptoren (NMDAR), stellt einen vollkommen neuen und vielversprechenden medikamentösen Ansatz in der Behandlung affektiver Störungen dar. In diesem sehr dynamischen Feld wurde bisher lediglich Spravato® (Esketamin) zugelassen; multiple weitere Substanzen befinden sich jedoch in der Entwicklung und Erprobung. In diesem Artikel soll ein narrativer kritischer Überblick über die wichtigsten Substanzen, Zielstrukturen und Entwicklungsfortschritte von NMDAR-Modulatoren gegeben werden.
Autres résumés
Type: Publisher
(ger)
Seit den ersten erfolgreichen Ketaminbehandlungen therapieresistenter depressiver Patienten werden schnell wirksame Antidepressiva intensiv beforscht. Der zugrunde liegende Wirkmechanismus der Beeinflussung des glutamatergen Systems, vorwiegend durch eine Modulation von N‑Methyl-D-Aspartat-Rezeptoren (NMDAR), stellt einen vollkommen neuen und vielversprechenden medikamentösen Ansatz in der Behandlung affektiver Störungen dar. In diesem sehr dynamischen Feld wurde bisher lediglich Spravato® (Esketamin) zugelassen; multiple weitere Substanzen befinden sich jedoch in der Entwicklung und Erprobung. In diesem Artikel soll ein narrativer kritischer Überblick über die wichtigsten Substanzen, Zielstrukturen und Entwicklungsfortschritte von NMDAR-Modulatoren gegeben werden.
Identifiants
pubmed: 34735585
doi: 10.1007/s00115-021-01221-x
pii: 10.1007/s00115-021-01221-x
doi:
Substances chimiques
Antidepressive Agents
0
Receptors, N-Methyl-D-Aspartate
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
234-242Informations de copyright
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Bahji A, Vazquez GH, Zarate CA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 278:542–555
doi: 10.1016/j.jad.2020.09.071
Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
doi: 10.1016/S0006-3223(99)00230-9
Bugarski-Kirola D, Blaettler T, Arango C et al (2017) Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry 82:8–16
doi: 10.1016/j.biopsych.2016.11.014
Canuso CM, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620–630
doi: 10.1176/appi.ajp.2018.17060720
Casarotto PC, Girych M, Fred SM et al (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 184:1299–1313
doi: 10.1016/j.cell.2021.01.034
Castrén E, Antila H (2017) Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry 22:1085–1095
doi: 10.1038/mp.2017.61
Daly EJ, Trivedi MH, Janik A et al (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76:893–903
doi: 10.1001/jamapsychiatry.2019.1189
Diazgranados N, Ibrahim L, Brutsche NE et al (2010) A randomized add-on trial of an N‑methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802
doi: 10.1001/archgenpsychiatry.2010.90
Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178:193–202
doi: 10.1176/appi.ajp.2020.20050596
Fukumoto K, Toki H, Iijima M et al (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361:9–16
doi: 10.1124/jpet.116.239228
Hansen KB, Yi F, Perszyk RE, Furukawa H et al (2018) Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol 150:1081–1105
doi: 10.1085/jgp.201812032
Henter ID, Park LT, Zarate CA (2021) Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs 35:527–543
doi: 10.1007/s40263-021-00816-x
Heresco-Levy U, Javitt DC, Gelfin Y et al (2006) Controlled trial of D‑cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 93:239–243
doi: 10.1016/j.jad.2006.03.004
FDA (2019) FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. http://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified . Zugegriffen: 23. Aug. 2021
Rote Liste (2021) Spravato® 28 mg Nasenspray, Lösung. https://www.arzneimitteltherapie.de/_Resources/Persistent/59bea9c351233c50859eb2276db807de2701e8c6/210222_Fachinformation%20Spravato.pdf . Zugegriffen: 23. Aug. 2021
GBA (2021) Tragende Gründe. https://www.g-ba.de/downloads/40-268-7781/2021-08-19_AM-RL-XII_Esketamin_D-659_TrG.pdf . Zugegriffen: 23. Aug. 2021
Horowitz MA, Moncrieff J (2020) Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry 27:1–4
Cision (2020) NeuroRx: phase 3 drug for suicidal bipolar depression to present at BIO CEO conference. https://www.prnewswire.com/news-releases/neurorx-phase-3-drug-for-suicidal-bipolar-depression-to-present-at-bio-ceo-conference-301001882.html . Zugegriffen: 23. Aug. 2021
Iadarola ND, Niciu MJ, Richards EM et al (2015) Ketamine and other N‑methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis 6:97–114
doi: 10.1177/2040622315579059
Kantrowitz JT, Halberstam B, Gangwisch J (2015) Single-dose ketamine followed by daily D‑cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 76:737–738
doi: 10.4088/JCP.14l09527
Kishi T, Matsunaga S, Iwata N (2017) A meta-analysis of memantine for depression. J Alzheimers Dis 57:113–121
doi: 10.3233/JAD-161251
Kishimoto T, Chawla JM, Hagi K et al (2016) Single-dose infusion ketamine and non-ketamine N‑methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46:1459–1472
doi: 10.1017/S0033291716000064
Leal GC, Bandeira ID, Correia-Melo FS et al (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271:577–582
doi: 10.1007/s00406-020-01110-5
McGirr A, Berlim MT, Bond DJ et al (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:693–704
doi: 10.1017/S0033291714001603
McGuire JF, Wu MS, Piacentini J et al (2017) A meta-analysis of D‑cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry 78:196–206
doi: 10.4088/JCP.15r10334
Rodriguez CI, Kegeles LS, Levinson A et al (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475–2483
doi: 10.1038/npp.2013.150
Schatzberg AF (2019) More thoughts on intranasal esketamine: response to Drevets et al. Am J Psychiatry 176:858–859
doi: 10.1176/appi.ajp.2019.19070688r
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522
doi: 10.1176/ajp.122.5.509
Zanos P, Moaddel R, Morris PJ et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486
doi: 10.1038/nature17998
Zarate CA, Singh JB, Carlson PJ et al (2006) A randomized trial of an N‑methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864
doi: 10.1001/archpsyc.63.8.856